GYRE Gyre Therapeutics, Inc.
Healthcare$6.06-1.94%ClosedMarket Cap: $587.8M
As of 2026-05-25
Valuation
P/E (TTM)
134.24
PEG
—
P/B
5.46
P/S
5.02
EV/EBITDA
216.04
DCF Value
$-0.55
FCF Yield
0.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
95.1%
Operating Margin
-0.1%
Net Margin
-5.4%
ROE
-6.3%
ROA
-3.9%
ROIC
0.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $22.5M | 94.6% | $-9.4M | $-8.6M | $— | — |
| Q4 null | $37.2M | 95.3% | $120.0K | $-1.7M | $— | — |
| FY null | $116.6M | 95.4% | $11.5M | $5.0M | $— | — |
| Q3 null | $30.6M | 94.7% | $6.9M | $3.6M | $— | — |
| Q2 null | $26.8M | 95.7% | $2.2M | $442.0K | $— | — |
| Q1 null | $22.1M | 95.9% | $2.3M | $2.7M | $— | — |
| Q4 null | $27.9M | 95.8% | $597.0K | $-99.0K | $— | — |
| FY null | $105.8M | 96.3% | $16.2M | $12.1M | $— | — |
| Q3 null | $25.5M | 96.2% | $4.2M | $1.1M | $— | — |
| Q2 null | $25.2M | 96.9% | $3.3M | $3.5M | $— | — |
| Q1 null | $27.2M | 96.4% | $8.1M | $7.5M | $— | — |
| Q4 2023 | $27.1M | 95.4% | $-91.6M | $-101.0M | $-0.68 | — |